Company Description
KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs.
The company’s product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE).
It develops Factor XIIa, an oral inhibitor for the treatment of HAE which is in preclinical trial. In addition, the company is developing an orally disintegrating tablet formulation, including KONFIDENT-KID for pediatric use with HAE; KONFIDENT-S for adolescent and adult patients with type I or type II HAE; and KONFIDENT for a potential oral therapy for HAE attacks.
The company is headquartered in Cambridge, Massachusetts.
| Country | United States |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 150 |
| CEO | Benjamin L. Palleiko |
Contact Details
Address: 55 Cambridge Parkway, Suite 901e Cambridge, Massachusetts 02142 United States | |
| Phone | (857) 999-0075 |
| Website | kalvista.com |
Stock Details
| Ticker Symbol | KALV |
| Exchange | NASDAQ |
| Fiscal Year | May - April |
| Reporting Currency | USD |
| CIK Code | 0001348911 |
| CUSIP Number | 483497103 |
| ISIN Number | US4834971032 |
| Employer ID | 20-0915291 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Benjamin L. Palleiko | Chief Executive Officer and Director |
| Dr. Christopher M. Yea Ph.D. | Chief Development Officer |
| Dr. Edward P. Feener Ph.D. | Chief Scientific Officer |
| Ryan Baker | Head of Investor Relations |
| Brian Krex J.D. | General Counsel |
| Jarrod Aldom | Vice President of Corporate Communications |
| Rachel M. Morten | Senior Vice President of Regulatory Affairs and QA |
| Dr. Michael D. Smith Pharm.D. | Senior Vice President of Development |
| Dr. Paul K. Audhya M.B.A., M.D. | Chief Medical Officer |
| Nicole Sweeny | Chief Commercial Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jul 16, 2024 | 144 | Filing |
| Jul 11, 2024 | 8-K | Current Report |
| Jul 11, 2024 | S-3 | Registration statement under Securities Act of 1933 |
| Jul 11, 2024 | 10-K | Annual Report |
| Jun 28, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |
| Apr 22, 2024 | 8-K | Current Report |
| Apr 1, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
| Mar 11, 2024 | 8-K | Current Report |
| Mar 11, 2024 | 10-Q | Quarterly Report |
| Mar 7, 2024 | 8-K | Current Report |